Conjugated estrogen/bazedoxifene (CE/BZA) therapy represents a new, 
progestin-free treatment in the management of postmenopausal health. CE/BZA 
pairs CE with the selective estrogen receptor modulator, BZA. The rationale for 
the development of CE/BZA was that BZA, acting primarily as a selective estrogen 
receptor degrader in uterine and breast tissue, would sufficiently inhibit the 
proliferative effects of CE on the endometrium. The absence of a progestin would 
reduce the incidence of uterine bleeding, breast pain and increased breast 
density associated with progestin-containing hormone therapy. CE/BZA has been 
evaluated in five multicenter, randomized, double-blind, placebo-controlled, and 
active-controlled Phase III trials known as the SMART trials. CE/BZA has been 
shown to maintain the established benefits of estrogen therapy for treatment of 
vasomotor symptoms and prevention of a loss in bone mineral density (bone mass), 
while minimizing certain estrogenic effects, particularly in the uterine 
endometrium and breast.